Keros Therapeutics (NASDAQ:KROS) Posts Earnings Results, Beats Estimates By $0.22 EPS

Keros Therapeutics (NASDAQ:KROS) released its quarterly earnings results on Wednesday. The company reported ($1.14) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.36) by $0.22, Zacks reports. Keros Therapeutics had a negative return on equity of 41.74% and a negative net margin of 27,890.94%. The firm had revenue of $3.04 million for the quarter, compared to analyst estimates of $37.32 million.

Keros Therapeutics Stock Performance

Shares of NASDAQ:KROS traded down $0.08 during mid-day trading on Friday, hitting $10.93. The stock had a trading volume of 148,478 shares, compared to its average volume of 1,573,935. The company has a market cap of $442.66 million, a PE ratio of -2.11 and a beta of 1.39. Keros Therapeutics has a 12-month low of $9.77 and a 12-month high of $73.00. The company’s 50 day moving average is $12.64 and its 200-day moving average is $39.79.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently issued reports on the stock. Oppenheimer reduced their price target on shares of Keros Therapeutics from $63.00 to $23.00 and set an “outperform” rating for the company in a research report on Thursday, January 16th. Wedbush downgraded shares of Keros Therapeutics from an “outperform” rating to a “neutral” rating and reduced their price target for the company from $47.00 to $15.00 in a research report on Friday, January 17th. Wells Fargo & Company reduced their price target on shares of Keros Therapeutics from $28.00 to $26.00 and set an “overweight” rating for the company in a research report on Thursday. Truist Financial reduced their price target on shares of Keros Therapeutics from $100.00 to $43.00 and set a “buy” rating for the company in a research report on Monday, December 23rd. Finally, Scotiabank reduced their price target on shares of Keros Therapeutics from $44.00 to $41.00 and set a “sector outperform” rating for the company in a research report on Thursday, January 16th. Six investment analysts have rated the stock with a hold rating and eight have given a buy rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $42.33.

Keros Therapeutics Company Profile

Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.